Fig. 11: Mechanism of BRAF (BRAF-V600E mutation) positive craniopharyngioma resistance.
From: New approaches to targeted drug therapy of intracranial tumors
The oncogenic role of BRAF mutations in papillary craniopharyngiomas is known, where it has been repeatedly proven that combination therapy with dabrafenib and trametinib has a positive effect.
